Oncostat

Oncostat

The recent revolution in –omics technology and the advent of targeted and immune therapies have increased the interest in molecular biomarkers capable of predicting the diagnostic, the clinical outcome of cancer patients or the response to specific therapies. The development of stratified medicine implies the segmentation of common cancers in small groups of tumors with specific abnormalities. A new generation of clinical trial designs requiring repeated biomarker measurements and surrogate clinical endpoints is needed to evaluate treatment effects in trials with limited sample sizes (research theme 1 "Clinical Trial Methodology"). Large-scale collaborative individual patient data (IPD) meta-analyses are useful tools to provide high level of evidence on the efficacy and toxicity of anti-cancer therapies in molecularly defined strata (theme 2 "Meta-analysis of treatments and biomarkers”). With the increasing number of therapies available for a specific indication in oncology, methods for network meta-analysis are being developed to compare their effectiveness. Because of the high costs associated with the tandem diagnostic and therapeutic medicine, economic analyses will be needed to evaluate the strategy associating the biomarkers with the molecularly targeted treatments, which represents a new field of research (theme 3 "Economic evaluation of treatments and biomarkers"). Once a potential biomarker has been identified for the prediction of diagnosis or clinical outcome of patients, an evidence-based evaluation implies careful replication in other cohorts. Advances in molecular genetics and in the knowledge of pathology of cancer are re-shaping the traditional methods in clinical epidemiology (theme 4 "Development and validation of biomarkers "). The statistical software packages developed in the team are available to the scientific community on the website https://github.com/Oncostat

Responsable(s)
Localisation

Hôpital Gustave Roussy, Bat. B2M

114 rue Edouard Vaillant
94805 Villejuif


Principaux Financeurs
Inserm
INCA
IReSP
Union Européenne
NIH

Membres

Raissa
KAPSO
Statisticien

Dernières publications

Single-use flexible bronchoscopes compared with reusable bronchoscopes: Positive organizational impact but a costly solution. Châteauvieux, C.; Farah, L.; Guérot, E.; Wermert, D.; Pineau, J.; Prognon, P.; Borget, I.; Martelli, N.. J Eval Clin Pract. 2018; 528-535: p.528-535. doi:10.1111/jep.12904
Article
Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting. Imbimbo, M.; Maury, J. M.; Garassino, M.; Girard, N.. Eur J Surg Oncol. 2018; : . doi:10.1016/j.ejso.2018.01.078
Article
Comparative analysis of durable responders on immune checkpoint inhibitors (ICI) versus other systemic therapies: A meta-analysis of phase III trials. Pons-Tostivint, Elvire; Latouche, Aurélien; Vaflard, Pauline; Ricci, Francesco; Loirat, Delphine; Sablin, Marie-Paule; Rouzier, Roman; Kamal, Maud; Morel, Claire; Lecerf, Charlotte; Servois, Vincent; Paoletti, Xavier; Le Tourneau, Christophe. JCO Precision Oncology. 2018; :
Article
Daily versus weekly prostate cancer image-guided radiotherapy: Phase 3 multicenter randomized trial. de Crevoisier, R.; Bayar, M. A.; Pommier, P.; Muracciole, X.; Pêne, F.; Dudouet, P.; Latorzeff, I.; Beckendorf, V.; Bachaud, J. M.; Laplanche, A.; Supiot, S.; Chauvet, B.; Nguyen, T. D.; Bossi, A.; Créhange, G.; Lagrange, J. L.. Int J Radiat Oncol Biol Phys. 2018; : . doi:10.1016/j.ijrobp.2018.07.2006
Article
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. Kandel, M.; Allayous, C.; Dalle, S.; Mortier, L.; Dalac, S.; Dutriaux, C.; Leccia, M. T.; Guillot, B.; Saiag, P.; Lacour, J. P.; Legoupil, D.; Lesimple, T.; Aubin, F.; Beylot-Barry, M.; Brunet-Possenti, F.; Arnault, J. P.; Granel-Brocard, F.; Stoebner, P. E.; Dupuy, A.; Maubec, E.; Grob, J. J.; Dreno, B.; Rotolo, F.; Ballon, A.; Michiels, S.; Lebbe, C.; Borget, I.. Eur J Cancer. 2018; 33-40: p.33-40. doi:10.1016/j.ejca.2018.09.026
Article

Thèses

Apport clinique des méta-analyses dans les cancers ORL localement avancés. Dirigée par Jean-Pierre Pignon & Pierre Blanchard. Lacas Benjamin. []: Paris Sud; .
Thesis
Incorporating historic information in multi-arm clinical trials for pediatric cancers. Abbas, Rachid. []: ; .
Thesis
Essais cliniques randomisés en oncologie en présence de sous-types rares identifiés par biomarqueur. Dirigée par Stefan Michiels. Bayar Mohamed Amine. []: Paris Sud; .
Thesis
Identification de sous-groupes à l'aide de biomarqueurs de grande dimension dans les essais randomisés. Dirigée par Stefan Michiels & Federico Rotolo. Belhechmi Shaima . []: Paris Sud; .
Thesis
Evaluation du coût et de la qualité de vie des patients atteints de mélanome métastatique : analyse des données de la cohorte MELBASE en vie réelle. Dirigée par Stefan Michiels & Isabelle Borget. Kandel Marguerite. []: Paris Sud; .
Thesis
Intégration de données multi-omiques pour la modélisation de l'impact de l'hétérogénéité inter-tumorale dans la survie de patients atteints de cancer. Rincourt, Sarah-Laure. []: Université Paris Saclay; .
Thesis